Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of FCF Margin data on record, last reported at 759.28% in Q3 2025.

  • For Q3 2025, FCF Margin rose 98595.0% year-over-year to 759.28%; the TTM value through Sep 2025 reached 80.03%, up 47477.0%, while the annual FY2024 figure was 55.47%, N/A changed from the prior year.
  • FCF Margin reached 759.28% in Q3 2025 per GLUE's latest filing, up from 144.79% in the prior quarter.
  • Across five years, FCF Margin topped out at 759.28% in Q3 2025 and bottomed at 3679.32% in Q1 2024.